DA, M., P, R., AC, D., M, I., NL, F., J, A. N., . . . D, W. (2019). Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers? The journal of prevention of Alzheimer's disease, 6(1), 20. https://doi.org/10.14283/jpad.2018.42
Chicago Style (17th ed.) CitationDA, Messner, et al. "Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence Is Meaningful to Patients, Providers, and Payers?" The Journal of Prevention of Alzheimer's Disease 6, no. 1 (2019): 20. https://doi.org/10.14283/jpad.2018.42.
MLA (9th ed.) CitationDA, Messner, et al. "Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence Is Meaningful to Patients, Providers, and Payers?" The Journal of Prevention of Alzheimer's Disease, vol. 6, no. 1, 2019, p. 20, https://doi.org/10.14283/jpad.2018.42.
